Navigation Links
InspireMD Reports Fourth Quarter and Fiscal Year 2013 Results
Date:9/17/2013

activities.  Healthlink will provide InspireMD with customer service center capabilities for inquiries from hospitals and distributors.  Healthlink will also handle all inventory controls, warehousing, shipping, and invoicing and receivables management for customers worldwide on behalf of InspireMD.

The Company began enrollment with its MASTER II clinical trial to evaluate the safety and effectiveness of the MGuard™ Prime EPS in patients suffering from ST Elevation Myocardial Infarction (STEMI). In total, the multi-center, randomized trial is expected to include up to 70 sites in the U.S. and Europe and as many as 1,114 patients. The results are intended to support the Company's Investigational Device Exemption (IDE) application with the U.S. Food and Drug Administration (FDA) to market the MGuard™ Prime MicroNet™ covered coronary stent system in the U.S.

The ongoing progress and changes throughout the Company are being driven by new leadership brought in over the past year at the executive management and board levels. To lead the Company forward, Mr. Milinazzo was appointed President and CEO in January 2013, bringing fifteen years of experience in interventional cardiology to InspireMD. The Company also appointed Ms. Gwen Bame to a newly created position of Vice President of Corporate Development and charged her with identifying and executing strategic programs and partnerships designed to meet InspireMD's global growth objectives.  As of yesterday, the Company appointed Mr. David Blossom as its Vice President of Global Marketing and Strategy and will be charged with creating and overseeing the implementation of a global strategic marketing plan.  At the Board level, industry veterans, Mr. Michael Berman and Dr. Campbell Rogers recently joined to provide invaluable strategic guidance and support.

Fourth Quarter Financial ResultsRevenue for the quarter ended June 30, 2013 was $1.5 million, an increase of 60
'/>"/>

SOURCE InspireMD
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. InspireMD Announces First Quarter 2012 Financial Results
2. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
3. InspireMD to Present at Inaugural Marcum Microcap Conference on June 20th in New York
4. InspireMD to Present at Harvard Investors Group on June 27 in New York
5. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
6. InspireMD Reports Results For Period Ending Sept. 30, 2012
7. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
8. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
9. InspireMD Reports Results for Period Ended Dec. 31, 2012
10. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
11. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... N.J., July 29, 2014  Covance Inc. (NYSE: ... quarter ended June 30, 2014.  Net revenue was $639 ... 2013.  On a GAAP basis, the company reported earnings ... The company reported pro forma earnings per diluted share ... 2013. Pro forma results exclude asset impairment charges totaling ...
(Date:7/29/2014)... 29  2014 ISPE—the International Society for Pharmaceutical ... Bournas as President and CEO, succeeding ... the Society last fall.  Mr. Bournas takes the ... healthcare association industry as well as significant international ... vision for the expansion of its global initiatives ...
(Date:7/29/2014)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) launched its presence ... Clinical Lab Expo today by unveiling two booths (#1209 ... partnering with customers to redefine the value of the ... that they,re looking for a partner to help them ... offices," said Jack Phillips , president and CEO ...
Breaking Medicine Technology:Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 4Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 5Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 6Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 7Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 8Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 9Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 10Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 11Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 12Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 13Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 14Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 15Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 16Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 17Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 18Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 19Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 20Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 21Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 22Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 23Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 24ISPE Hires Healthcare Association Exec as CEO 2ISPE Hires Healthcare Association Exec as CEO 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 4
... -- China Medical Technologies, Inc. (the "Company") (Nasdaq: ... in-vitro diagnostic ("IVD") company, today announced that its ... ("GP Medical") and Beijing Yuande Bio-Medical Engineering Co., ... 415th, respectively, in the Deloitte Technology Fast 500 ...
... SUNNYVALE, Calif., Dec. 5, 2010 Pharmacyclics, Inc. (Nasdaq: ... Chronic Lymphocytic Leukemia (CLL) presentations at the American Society ... PCI-32765.  Two presentations report preclinical data, and one presentation ... patients with CLL or Small Lymphocytic Lymphoma (SLL) treated ...
Cached Medicine Technology:China Medical Technologies Announces its Subsidiaries, GP Medical and Beijing Yuande, Ranked 12th and 415th, respectively, in Deloitte Technology Fast 500 Asia Pacific 2010 Program 2Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 2Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 3Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 4Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 5Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 6Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 7
(Date:7/30/2014)... Regents Health Resources, a consulting firm traditionally specializing ... industry veteran Daryl Demonbreun and former St. Thomas executive ... ambitious plans to grow into a full-service health care ... at a steady pace for nearly 20 years, but ... Bob Maier, founder and chief executive officer of Regents ...
(Date:7/29/2014)... Saint Luke’s Medical Group’s 11 ... Patient-Centered Medical Home 2011 Level 3 Recognition—the highest ... Assurance. Only one out of four physicians' groups ... or Level 3 recognition. , Patients of primary ... report faster access to their doctors, better outcomes ...
(Date:7/29/2014)... The Mesothelioma Applied Research Foundation (Meso ... led advocacy efforts among its members for increased ... Caucus on the Deadliest Cancers. , As a ... following 20 members: , Rep. Matt Salmon (AZ-5) – June ... Rep. Zoe Lofgren (CA-19) – June 19, 2014, Rep. Adam ...
(Date:7/29/2014)... Colorado (PRWEB) July 29, 2014 The One ... created by Alison Freeman, an herbal medicine specialist. Alison Freeman ... their herpes condition. , People interested in finding out ... Internet and can download it, as it is currently available ... a variety of natural remedies and herbal medicine tips that ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Daily Gossip reveals ... created by a holistic nutritional and functional medicine practitioner, who ... overcoming this problem. , Karen suffered from leaky gut, too, ... time to develop this unique treatment. , Karen Brimeyer ... with sufferers from all around the world. The author of ...
Breaking Medicine News(10 mins):Health News:Sferrella and Demonbreun Join Regents Health Resources 2Health News:Saint Luke’s Medical Group Awarded Patient-Centered Medical Home 2011 Level 3 Recognition 2Health News:Mesothelioma Organization Works to Add Members to ‘Deadliest Cancer Caucus’ 2Health News:Mesothelioma Organization Works to Add Members to ‘Deadliest Cancer Caucus’ 3Health News:One Minute to Herpes Cure Review Reveals Simplest Herpes Treatment 2Health News:Leaky Gut Cure Review Reveals Karen Brimeyer’s Natural Way to Heal Leaky Gut 2
... the real thing may go further than first thought.Violent ... that makes people more likely to behave aggressively, says ... considered the effects of popular games such as Doom, ... killings, high-powered weaponry and street crime, indicates that avid ...
... Milwaukee Cardiologist, and Chief of the Specialty Hospital in ... dire need of a shot in the arm.//Specialty Hospitals ... prevailing healthcare systems, was nipped in the bud, owing ... opinion write-up in The Wall Street Journal, has expressed ...
... in every 100,000 in India suffer from stroke every year. ... Tamil Nadu for promoting awareness with regard to stroke in ... is very low.// ,The Indian Stroke Association ... a study report here which says around 20 million people ...
... between office work and private life, as they feel that ... during evenings and weekends //when they are with their family ... hours they find the mobile phones and pagers ringing from ... and work concentration. Most of the people feel that work ...
... and Industrial Research Organization (CSIRO) may increase the ... Nutritionist. //Dr. Stanton has asked the Australian Prime ... in recommending CSIRO diet as it contains high ... recommend the Australian Governments Australian Guide to Healthy ...
... Orr, a Canadian woman who has survived breast cancer twice, ... Herceptin. //Orr says that the life-saving and life-improving drug should ... deadly cancer have a chance of successfully fighting it. ... drug is federally funded in some provinces, while it is ...
Cached Medicine News:Health News:Violent computer games spur aggression: study 2
Molt periosteal elevator #9, 18.5 cm, 7-1/4"....
Periosteal elevator #9, 18 cm, 7"....
Full curve periosteal elevator - cervical - sharp, round tip, length 184 mm (7 1/4")....
... The Frontier Anterior Deformity System ... Kass, Moss Miami, and Isola ... thoracoscopic procedures to deliver unsurpassed versatility, ... the highest level of versatility for ...
Medicine Products: